Contact CFFC

Sep

Clinical Trial -September 2018

Cystic Fibrosis Foundation distributed the following clinical trial update in September. Click the trial title to get more details.

The following alert was issued on July 11:

Phase 2 study of PTI-428 drug in people with CF ages 18 and older who have two copies of the F508del CFTR mutation

Description: This randomized, placebo-controlled study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability of the drug PTI-428 and how it is processed by the body. It is for people with CF ages 18 and older who have two copies of the F508del CFTR mutation and are already taking tezacaftor/ivacaftor.

Status: Enrolling

Age: 18 Years and Older

Mutation: Two Copies F508del

Fev1% Predicted: 40 to 90%

Number of Visits: 10

Length of Participation: 74 days

ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT03591094


Comments are closed.